Welcome to our dedicated page for Clever Leaves Holdings news (Ticker: CLVRW), a resource for investors and traders seeking the latest updates and insights on Clever Leaves Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clever Leaves Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clever Leaves Holdings's position in the market.
Clever Leaves Holdings reported Q3 2021 revenue of $4.0 million, a 3% increase from Q3 2020. Gross profit rose 22% to $2.5 million, with a gross margin of 62.9%. The expansion of its cultivation facility in Portugal was completed ahead of schedule, increasing operational capacity. However, net income was $1.0 million, up from a net loss of $(6.1) million last year, influenced by gains from warrant liabilities. The company revised its 2021 revenue outlook, now expecting $14 to $16 million, down from a prior range of $17 to $20 million.
Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) will hold a conference call on November 10, 2021, at 5:00 p.m. Eastern time to discuss its third-quarter results for the period ending September 30, 2021. Financial results will be published in a press release before the call. The call includes a management discussion followed by a Q&A session. Interested participants should join 5-10 minutes early. A replay of the call will be available after 8:00 p.m. Eastern time on the same day through November 17, 2021.
Clever Leaves Holdings (NASDAQ: CLVR, CLVRW) announced a partnership with Pharmalab PHL Laboratories in Colombia to distribute pharmaceutical-grade cannabinoid formulations. This agreement follows new regulations permitting drugstores to sell medicinal cannabinoids. Clever Leaves, certified in Good Manufacturing Practices, aims to provide high-quality cannabinoid products to Colombian patients. Both companies emphasize the therapeutic potential of these products for inflammatory conditions. The partnership highlights Colombia's role as a leader in the Latin American cannabinoid market.
Clever Leaves Holdings (NASDAQ: CLVR, CLVRW) announced the successful export of 30 kg of high-THC cannabis flower from Portugal to Biopharmaceutical Research Company (BRC), a DEA-licensed firm in the U.S., marking a significant milestone in entering the U.S. cannabis market. This shipment, compliant with pharmaceutical standards, will support BRC’s projects in plant-based therapeutics. The companies have fostered a partnership through Project Change Lives, aimed at advancing medical cannabis research with a projected contribution of up to $25 million.
On October 4, 2021, Clever Leaves Holdings Inc. (Nasdaq: CLVR) announced its participation in several investor events in October. Key events include the A.G.P. Virtual Fall Consumer Cannabis Conference on October 5, the Lytham Partners Fall 2021 Investor Conference on October 7, and a panel at MJBizCon in Las Vegas on October 14, with in-person attendance from October 20-22. Additionally, Clever Leaves will present at the Benzinga Cannabis Capital Conference on October 15. The company focuses on sustainable large-scale cannabis cultivation and processing, with operations worldwide.
Clever Leaves Holdings reported a remarkable 89% revenue increase to $3.7 million in Q2 2021, up from $1.9 million a year prior. Gross profit surged 157% to $2.3 million, achieving a 63.6% gross margin. Despite a net loss of $(9.0) million, the company has reaffirmed its FY2021 guidance. The launch of several global partnerships helped expand its distribution network, with a new $25 million financing enhancing liquidity. The Colombian government’s decree permitting medical cannabis flower exports is expected to significantly expand the market potential for Clever Leaves.
Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) announces its collaboration with the University of Missouri’s pediatric neuroscience lab as part of its Project Change Lives Campaign. The initiative will provide up to $25 million in medical cannabis products to support research on CBD’s effectiveness for neurodevelopmental disorders, including autism and epilepsy. This partnership is expected to enhance the scientific understanding of cannabis-derived treatments.
Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) will host a conference call on August 12, 2021, at 5:00 p.m. ET to discuss its Q2 2021 results. The company will issue a press release with its financial results before the call. Interested parties can join via toll-free or international dial-in numbers, with a conference ID of 21996432. A live broadcast and replay will be available post-call. Clever Leaves is recognized for its sustainable cannabis operations across multiple countries with various international certifications.
Clever Leaves has partnered with Ethypharm, a European pharmaceutical firm, to market EU-GMP certified medical cannabis products in Germany. The deal involves high-CBD and high-THC formulations aimed at treating Central Nervous System diseases and chronic pain. Clever Leaves’ CEO, Kyle Detwiler, emphasizes this partnership as a significant step into the German market, which is critical for growth in Europe. Clever Leaves holds multiple international certifications, enhancing its operational capabilities for global distribution.